Since June 2025, Klinik Hirslanden in Zurich has been offering an additional CAR T-cell product, CARVYKTI, for the treatment of multiple myeloma (bone marrow cancer). This new therapy complements the CAR T-cell treatments already established at our clinic since late 2019, which have been successfully used to treat both bone marrow cancer and lymphoma.
This advanced immunotherapy is intended for patients with multiple myeloma who no longer respond adequately to other cancer treatments. Switzerland is among the first five countries worldwide where CARVYKTI is available. Within Switzerland, Klinik Hirslanden Zurich is one of the few specialized centers offering this highly advanced therapy.
CAR T-cell therapy is based on the genetic modification of the patient’s own T cells – white blood cells that play a central role in the immune system.
With CARVYKTI, the collected T cells are equipped with a so-called chimeric antigen receptor (CAR), which specifically targets the B-cell maturation antigen (BCMA) – a protein mainly found on malignant plasma cells. After reinfusion into the body, these modified cells can specifically recognize and destroy the cancer cells, which had previously gone undetected by the natural immune system.
You can find more information about CAR T-cell therapy at Klinik Hirslanden Zurich hier.
For questions regarding CAR T-cell therapy or the referral of suitable patients, Prof. Dr. med. Christoph Renner, Director of the Medical Cell Therapy Program at Klinik Hirslanden in Zurich, is available at +41 44 387 37 80.
